21.5 C
New York
Tuesday, June 6, 2023

Amedisys Inc. (NASDAQ: AMED): Is It A Buying Opportunity Again?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Amedisys Inc. (AMED) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.11, or 0.14%, to $76.55. The Amedisys Inc. has recorded 5,530 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that AMEDISYS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES 2023 GUIDANCE.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Stocks Info

AMED belongs to the Healthcare sector of the NASDAQ while operating in the Medical Care Facilities industry. At the end of the last regular session, the stock closed at $76.44 and fluctuated between $78.92 as its day high and $75.80 as its day low. The current market capitalization of Amedisys Inc. is $2.51B. A total of 0.59 million shares were traded on the day, compared to an average of 558.50K shares.

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, AMED has seen 7 BUY and 6 SELL insider trades, representing the acquisition of 57,202 and the disposition of 26,247 shares. Over the last 12 months, there were 19 BUYs and 14 SELLs from insiders. Insiders purchased 153,265 shares during that period but sold 38,007.

In the most recent transaction, North Michael Paul sold 5,908 shares of AMED for 86.43 per share on Mar 03. After the transaction, the Chief Information Officer now owns 4,164 company shares. In a previous transaction on Jun 23, Bohnert Denise M. sold 557 shares at 115.00 per share. AMED shares that Chief Compliance Officer owns now total 11,850.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for AMED in the last 3 months, the mean price target is $93.92 with high estimates of $115.00 and low estimates of $73.00. In terms of 52-week highs and lows, AMED has a high of $131.32 and a low of $69.36.

As of this writing, AMED has an earnings estimate of $1.09 per share for the current quarter. EPS was calculated based on a consensus of 14 estimates, with a high estimate of $1.15 per share and a lower estimate of $0.97. The company reported an EPS of $1.16 in the last quarter, which was 16.00% higher than expectations of $1.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. AMED’s latest balance sheet shows that the firm has $42.69M in Cash & Short Term Investments as of fiscal 2021. There were $545.61M in debt and $374.28M in liabilities at the time. Its Book Value Per Share was $33.14, while its Total Shareholder’s Equity was $976.32M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AMED is Buy with a score of 3.57.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles